Telemus Capital, LLC Regeneron Pharmaceuticals, Inc. Call Options Transaction History
Telemus Capital, LLC
- $1.2 Billion
- Q4 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REGN
# of Institutions
1,426Shares Held
82.1MCall Options Held
835KPut Options Held
1.46M-
Vanguard Group Inc Valley Forge, PA8.93MShares$9.33 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$8.95 Billion0.19% of portfolio
-
Jpmorgan Chase & CO New York, NY7.73MShares$8.07 Billion0.68% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.06 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.86 Billion0.76% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $112B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...